ENSC

Ensysce is a pre-revenue, clinical-stage pharma whose MD&A states plainly that it has 'not generated any revenue from product sales' and 'may never become profitable' — the $5.07M of FY2025 'revenue' is grant/collaboration income, not a product business, and it actually shrank 2.8% YoY. The company burned $7.81M in operating cash against just $4.31M of cash on hand, implying well under a year of runway before the next raise. The filing itself flags that these conditions 'raise substantial doubt' about its ability to continue as a going concern, and repeatedly warns that financing will come through equity or convertible debt that will dilute existing holders. That dilution has already been brutal: shares outstanding rose 560% YoY and diluted EPS was -$3.98, hallmarks of a share count reset and serial capital raises that have driven accumulated deficit to -$140M.

The capital structure is deteriorating fast. Total liabilities doubled (+106%) to $4.57M while equity fell 13% to $3.21M, pushing liabilities/equity to 1.42x. Operating margin is -202% and ROE is -317% — figures that only make sense for a company spending $10.4M on R&D with no marketable product. The entire enterprise is a bet on the pipeline: PF614 (an abuse-deterrent oxycodone prodrug) in Phase 3, PF614-MPAR in Phase 1b, and nafamostat pre-Phase 1. None has completed a pivotal trial or won approval, and the company has never manufactured at commercial scale or sold anything.